CClinicalTrials.gg
CompletedNCT02255188Updated Sep 8, 2017

Experimental Study of the Vascular Prosthesis Manufactured by Electrospinning

An observational study in ARTERIAL OCCLUSIVE DISEASE, sponsored by Meshalkin Research Institute of Pathology of Circulation. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-08.

Sponsored by Meshalkin Research Institute of Pathology of Circulation · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether the Vascular prosthesis manufactured by Electrospinning is safe with respect to the development of thrombosis.

Read the detailed description

To test the influence of the prostheses to hemostasis blood will be pumped through the vascular prosthesis or control silicone tube (both with identical inner diameter 1,7 mm) during 20 minutes at a linear velocity 10 cm/sec (corresponding to 18 ml/min). The tested prostheses (or control tubes) will be installed between two syringes with blood installed in the UTPS-1 instrument providing synchronical movement of pistons of both syringes. Installing UTPS-1 was designed and manufactured at the Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences consists of a mechanical pushers, equipped with clamps for syringes and pistons, stepper motor, electronic control unit and power supply.

UTPS-1 and polypropylene non-pyrogenic syringes filled with blood without any bulbs of air provides absence of contacts with air, pyrogens and minimize lysis of blood cells. UTPS-1 has no analogues, and does not require licensure, metrological control or obtaining of any other permits.

After pumping the blood will be separated into plasma and cell fraction according to standard laboratory methods. Primary blood (before any treatment), blood after pumping through silicon tube (control), and vascular prosthesis will be tested for hemostatic parameters.

Notification of basic and additional parameters being studied, which will be

evaluated in the study:

  1. The initial parameters of blood hemostasis will be evaluated (Platelet count; Platelet aggregation; Prothrombin time, International Normalised Ratio [INR], activated partial thromboplastin time (aPTT), prothrombin Quick, thrombin time, soluble fibrin monomer complexes (SFMC), free hemoglobin and P- selectin concentrations).
  2. To evaluate the influence of the prosthesis to circulating blood the same hemostasis characteristics wiil be evaluated in blood after 20 min of circulation through prosthesis and silicon tube (Platelet count; Platelet aggregation; Prothrombin time, International Normalised Ratio [INR], activated partial thromboplastin time (aPTT), prothrombin Quick, thrombin time, soluble fibrin monomer complexes (SFMC), the measurement of free hemoglobin, P- selectin).
  3. Microscopy: a study of adhesion of blood cells on the surface of the prosthesis

Description of Design of the Research: this will be prospective (are marked in section Detailed Description)

Monocentred research

Defined indicators for each prosthesis

  1. hemostasis characteristics listed hereinabove for untreated blood (control)

2 hemostasis characteristics listed hereinabove in blood after 20 min circulation through silicone tube (control)

3 hemostasis characteristics listed hereinabove in blood after 20 min circulation through After the interaction with the experimental vascular prosthesis

Will be studied 4 types of vascular prostheses made by electrospinning

  • polycaprolactone;
  • polycaprolactone / gelatin/poorly permeable layer;
  • polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer;
  • nylon 6
02

Conditions studied

  • ARTERIAL OCCLUSIVE DISEASE

Keywords

  • Haemostas, prosthesis
03

In context

Arterial Occlusive Diseases

296 studies on the registry are indexed under Arterial Occlusive Diseases; 46 are open to participants now.

This study's enrollment of 120 is below the median of 183 across 75 observational studies indexed under Arterial Occlusive Diseases.

Browse Arterial Occlusive Diseases studies →

Lead sponsor

Meshalkin Research Institute of Pathology of Circulation is the lead sponsor of 114 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

volunteers, donors

Inclusion criteria

  • Male or female aged from 18 to 50 years at the date of the informed consent signing;
  • Patients without atherosclerosis
  • Patients without blood pathology

Exclusion criteria

Exclusion Criteria:

  • Patient did not sign the informed consent.
  • Early postoperative period.
  • Concomitant diseases such as atherosclerosis, blood pathology, venous thrombosis, malignancy, terminal cancer, infectious - inflammatory disease at the time of the study.
  • Patients after implantation of a cardioverter-defibrillator; prior prosthetic heart valves or other implants, which can lead to mechanical damage to the blood cells.
  • Receiving anticoagulants, antiplatelet, antibacterial drugs, NSAIDs.
  • Myocardial infarction less than 3 months ago.
  • Irreversible failure of major organs with an expected survival time of less than 1 year
  • Pregnancy, lactation.
  • Age above 50 years.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (actual)
Patient registry
No

Groups and cohorts

  • Graft type - PCL

    PCL - polycaprolactone

    Procedure: blood sampling procedure

  • Graft type - PCL/ gelatin

    polycaprolactone/ gelatin/poorly permeable layer;

    Procedure: blood sampling procedure

  • Graft type - PLGA/PCL/gelatin

    PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer

    Procedure: blood sampling procedure

  • Graft type - nylon 6

    Procedure: blood sampling procedure

Interventions

  • Procedureblood sampling procedure

    30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary

06

What researchers measure

Primary outcomes

  1. Number of participants (blood samples) having a higher degree of aggregation of platelets after interaction with the prosthesis, as a sign of thrombosis. (with ristomycin, adrenaline, collagen, ADP)

    percentage

    Time frame: during the day

Secondary outcomes

  1. Platelet count

    cells / L

    Time frame: during the day

  2. Prothrombin time

    seconds

    Time frame: during the day

Other outcomes

  1. International Normalised Ratio

    Time frame: during the day

  2. activated partial thromboplastin time

    seconds

    Time frame: during the day

  3. prothrombin Quick

    Time frame: during the day

  4. thrombin time

    seconds

    Time frame: during the day

  5. soluble fibrin monomer complexes

    0-4mg/100ml

    Time frame: during the day

  6. free hemoglobin

    g / l

    Time frame: during the day

  7. P- selectin concentrations

    ng / ml

    Time frame: during the day

  8. Adhesion of blood cells on the surface of the prosthesis

    microscopy

    Time frame: during the day

07

Study locations

1 site
  • popova Irina
    Novosibirsk, Novosibirskay obl. 630055, Russian Federation
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02255188
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Responsible party
Sponsor
First posted
Oct 2, 2014
Start date
Oct 2014
Primary completion
Oct 2015
Completion
Nov 2015
Last update
Sep 8, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion